paclitaxel + cisplatin (Far Eastern Memorial Hospital)

This intraperitoneal (IP) chemotherapy regimen, specifically evaluated at Far Eastern Memorial Hospital, is a combination treatment for advanced ovarian, fallopian tube, and primary peritoneal cancers. The protocol involves a sequence of intravenous (IV) paclitaxel (135 mg/m² on day 1) followed by intraperitoneal administration of cisplatin (75-100 mg/m² on day 2) and paclitaxel (60 mg/m² on day 8). Paclitaxel functions as a microtubule-stabilizing agent that inhibits mitosis by preventing the depolymerization of tubulin. Cisplatin is a platinum-based cytotoxic drug that forms covalent DNA cross-links, interfering with DNA replication and transcription to induce apoptosis. This regional delivery method aims to achieve significantly higher drug concentrations within the peritoneal cavity, the primary site of disease spread in ovarian cancer, compared to standard systemic intravenous administration.

Other names

intraperitoneal chemotherapyIP chemotherapyFEMH IP regimenintraperitoneal cisplatin and paclitaxel